Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
Jabez heads for the clinic
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
